title: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
abstract: Hormone-driven expression of the ERG oncogene after fusion with TMPRSS2 occurs in 30% to 70% of therapy-naive prostate cancers. Its relevance in castration-resistant prostate cancer (CRPC) remains controversial as ERG is not expressed in some TMPRSS2-ERG androgen-independent xenograft models. However, unlike these models, CRPC patients have an increasing prostate-specific antigen, indicating active androgen receptor signaling. Here, we collected blood every month from 89 patients (54 chemotherapy-naive patients and 35 docetaxel-treated patients) treated in phase I/phase II clinical trials of an orally available, highly specific CYP17 inhibitor, abiraterone acetate, that ablates the synthesis of androgens and estrogens that drive TMPRSS2-ERG fusions. We isolated circulating tumor cells (CTC) by anti-epithelial cell adhesion molecule immunomagnetic selection followed by cytokeratin and CD45 immunofluorescence and 4',6-diamidino-2-phenylindole staining. We used multicolor fluorescence in situ hybridization to show that CRPC CTCs, metastases, and prostate tissue invariably had the same ERG gene status as therapy-naive tumors (n=31). We then used quantitative reverse transcription-PCR to show that ERG expression was maintained in CRPC. We also observed homogeneity in ERG gene rearrangement status in CTCs (n=48) in contrast to significant heterogeneity of AR copy number gain and PTEN loss, suggesting that rearrangement of ERG may be an earlier event in prostate carcinogenesis. We finally report a significant association between ERG rearrangements in therapy-naive tumors, CRPCs, and CTCs and magnitude of prostate-specific antigen decline (P=0.007) in CRPC patients treated with abiraterone acetate. These data confirm that CTCs are malignant in origin and indicate that hormone-regulated expression of ERG persists in CRPC.
authors.affiliation: The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
authors.forename: Gerhardt
authors.initials: G
authors.lastname: Attard
authors.forename: Joost F
authors.initials: JF
authors.lastname: Swennenhuis
authors.forename: David
authors.initials: D
authors.lastname: Olmos
authors.forename: Alison H M
authors.initials: AH
authors.lastname: Reid
authors.forename: Elaine
authors.initials: E
authors.lastname: Vickers
authors.forename: Roger
authors.initials: R
authors.lastname: A'Hern
authors.forename: Rianne
authors.initials: R
authors.lastname: Levink
authors.forename: Frank
authors.initials: F
authors.lastname: Coumans
authors.forename: Joana
authors.initials: J
authors.lastname: Moreira
authors.forename: Ruth
authors.initials: R
authors.lastname: Riisnaes
authors.forename: Nikhil Babu
authors.initials: NB
authors.lastname: Oommen
authors.forename: George
authors.initials: G
authors.lastname: Hawche
authors.forename: Charles
authors.initials: C
authors.lastname: Jameson
authors.forename: Emilda
authors.initials: E
authors.lastname: Thompson
authors.forename: Ronald
authors.initials: R
authors.lastname: Sipkema
authors.forename: Craig P
authors.initials: CP
authors.lastname: Carden
authors.forename: Christopher
authors.initials: C
authors.lastname: Parker
authors.forename: David
authors.initials: D
authors.lastname: Dearnaley
authors.forename: Stan B
authors.initials: SB
authors.lastname: Kaye
authors.forename: Colin S
authors.initials: CS
authors.lastname: Cooper
authors.forename: Arturo
authors.initials: A
authors.lastname: Molina
authors.forename: Michael E
authors.initials: ME
authors.lastname: Cox
authors.forename: Leon W M M
authors.initials: LW
authors.lastname: Terstappen
authors.forename: Johann S
authors.initials: JS
authors.lastname: de Bono